NOV 24, 2018 10:54 PM PST

New Anti-Malarial Drug Target in Cancer

WRITTEN BY: Nouran Amin

For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have never been quite understood until a recent research study in Cancer Discovery.

Credit: NaturalNews.com

The research, carried at out Abramson Cancer Center of the University of Pennsylvania, identified the chloroquines specific target in cancer – an enzyme called PPT1. Identifying that particular enzyme has opened the doors for potential cancer treatments. “The discovery of this target is critical because chloroquines are currently being evaluated in clinical trials all over the world, including here at Penn, and this knowledge fundamentally changes the way we look at those trials,” says study co-senior author and associate professor--Dr Ravi K. Amaravadi of the Perelman School of Medicine at the University of Pennsylvania.

The enzyme, PPT1, controls the target of rapamycin (mTOR)—which is highly involved in the growth of cancer cells as well as another cellular process known as autophagy—a way for cancer cells to detoxify and repair themselves. The mechanisms of autophagy was discovered by Nobel Prize winner-- Yoshinori Ohsumi, watch the video below to learn more:

In previous studies, autophagy was found to provide nutrient support for mTOR to direct cancer growth while, interestingly, mTOR was found to shut down autophagy when nutrients aren’t needed. Using these studies, the researchers utilized CRISPR/Cas9 gene editing approach to knockout PPT1 from cancer cells and observe if the same effects in earlier research can be seen. Results showed that indeed removing ppt1 does slow tumor growth. “The edited cells look like they’ve been treated with a drug, and they grow significantly slower than the unedited cells,” Prof Amaravadi said. “We also compiled data from existing databases and found PPT1 is both highly expressed in most cancers and also associated with poor outcomes.”

These findings encouraged researchers to develop potent chloroquine known as DC661, that will take advantage of this novel treatment pathway.

“We now have a specific molecular target in cancer, as well as a potent way to reach it,” Prof Amaravadi said. “It not only provides new context for current clinical trials involving hydroxychloroquine, but also, with further development of these compounds toward clinical drug candidates, it opens the door for head-to-head testing of our compounds or their optimized derivatives versus current chloroquines to see which is more effective.”

Source: Drug Target Review

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Drug Increases Survival Rates for Heart Failure Patients
Scientists have demonstrated in preclinical studies that a drug called ‘Aliskiren’ works by inhibiting the activity of an enzyme involved in bl...
NOV 20, 2019
Microbiology
NOV 20, 2019
Antibody Discovered That May be the Key to a Universal Flu Vaccine
Instead of designing a new flu vaccine every year, researchers have made a breakthrough that may lead to a single vaccine that protects against all strains....
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Can Aspirin Prevent a Brain Bleed?
Can aspirin prevent a brain bleed? To answer the questions, researchers rummaged through a database system looking to see an association between aspirin us...
NOV 20, 2019
Cannabis Sciences
NOV 20, 2019
Cannabis Can't Simply Replace Opioids for Pain Management
According to the research, cannabis is not effective when it comes to treating individuals struggling with opioid use disorder. While some may have conside...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Experimental Cholesterol-Lowering Drug
A recent study shows that patients who take a maximum dose of statin drugs in addition to a twice-yearly injection of the experimental cholesterol-lowering...
Loading Comments...